LeiZhengMD

Oncology • San Antonio, TX

UT Health San Antonio – Executive Director, Mays Cancer Center, Vice President for Oncology

Join to view full profile

Dr. Zheng is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Zheng's full profile

Already have an account?

Office
7979 Wurzbach Road
Mail Code 8026, Office U632A
San Antonio, TX 78229

Summary

Dr. Lei Zheng is an oncologist in San Antonio, TX. He received his medical degree from Peking Union Medical College and has been in practice 21 years. He also speaks multiple languages, including Chinese (Mandarin). He is experienced in pancreatic cancer, immunotherapy, gastroenterology, oncology, and personalized medicine. He has more than 150 publications and over 10,000 citings.

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2006 - 2009
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 2003 - 2006
Peking Union Medical CollegeClass of 1996

Certifications & Licensure

MD State Medical License 2006 - 2025
PA State Medical License 2020 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Trial of Boost Vaccinations of Pancreatic Tumor Cell Vaccine Start of enrollment: 2010 Apr 20
Active, not recruiting
Phase 2
Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma Start of enrollment: 2013 Jan 01
Active, not recruiting
Phase 2
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
Completed
Phase 2
Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer Start of enrollment: 2016 Jul 18
Completed
Phase 2
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma Start of enrollment: 2019 Jun 04
Recruiting
Phase 2
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. Start of enrollment: 2019 Dec 12
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Survival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma.
Alex B Blair, Shannon N Radomski, Joanne Chou, Mengyuan Liu, Thomas Clark Howell
Annals of Surgical Oncology. 2025-03-01
Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer.
Nan Niu, Keyu Li, Junke Wang, Vanessa Funes, Birginia Espinoza
Biomarker Research. 2025-01-27
CD137 agonism enhances anti-PD1 induced activation of expanded CD8T cell clones in a neoadjuvant pancreatic cancer clinical trial.
Janelle M Montagne, Jacob T Mitchell, Joseph A Tandurella, Eric S Christenson, Ludmila V Danilova
Iscience. 2025-01-17

Press Mentions

Renowned Oncologist, Zheng, Brings $500,000 UT System STARs Award to UT Health San AntonioJanuary 10th, 2025
UT Health San Antonio World-Renowned Expert in BRCA Research to Be Honored for Global ContributionsOctober 21st, 2024
UT Health San Antonio Joined UTSA Roadrunners in Salute to Health Care WorkersOctober 21st, 2024
Join now to see all

Other Languages

Chinese (Mandarin)

External Links

Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/lei-zheng